Hepatitis C is a disease of clinical importance because of its high infection rate in blood donors and its persistence as chronic infections which may lead to cirrhosis and hepatocellular carcinoma in the long term. The variability of the HCV genome has posed difficulties in serological detection and vaccine design. The recent advance in phage technology offers a means of cloning human anti-HCV antibodies of a defined specificity that may have potential therapeutic use. We now report the generation of a phage display library using the V H genes of a HCV-infected patient and the V L genes of two non-immune individuals. From this library we were able to obtain specific IgG single-chain Fvs (scFvs) that recognize viral core and envelope proteins by selection on synthetic peptides derived from the core sequence PKARRPEGRTWAQPG and the envelope E2 sequence RPIDDFDQGWGPITY. The specificity of the scFvs was demonstrated by their specific reactions with homologous peptides in ELISA and the specific blocking of scFv binding by homologous peptides, in a dose-dependent manner, in inhibition ELISA. The binding of the anticore 4c2 to homologous peptide was blocked by HCV-positive human sera in an antibody-concentration-dependent manner, suggesting that the scFv recognizes a similar if not identical epitope to those of one or more of the polyclonal antibodies present in the sera.
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functionally conserved surface domains common to various genotypes (Trkola et al., 1995) . Already there is in vitro and in vivo evidence that HCV infection elicits a neutralizing antibody response in humans (Farci et al., 1994; Zibert et al., 1995) . The virus envelope protein is the primary target for the host immune system. Despite the high variability of the HCV envelope sequence, certain domains of biological importance e.g. ligands required in viral attachment to host cell receptors, have to be preserved. Antibodies specific for the hypervariable region (HVR1) within the envelope E2 protein have been shown to be cross-reactive with two HCV variants (Scarselli et al., 1995) and to be able to block viral attachment to cultured human fibroblast cells (Zibert et al., 1995) . Most HCV carriers ( > 95 %) appear to have low titres of anti-envelope antibodies (Chien et al., 1993) . However, attempts to obtain human monoclonal anti-HCV antibodies were only successful with the random process of Epstein-Barr virus-transformation (Akatsuka et al., 1993; Siemoneit eta]., 1994) . In order to obtain rare human anti-HCV antibodies of a particular specificity, we have mimicked the antigen-driven selection process of the immune system using phage antibody technology (McCafferty et al., 1990; Winter & Milstein, 1991) , which involves the cloning of V n and V• genes amplified from a human source and the surface display of the proteins derived from them attached to the gene III product of the filamentous phage. Specific antibodies were obtained by sequential rounds of selection on proteins or haptens (Marks et al., 1991a) . Application of the technology for the therapeutic treatment of viral infections seems promising and, if feasible, would open up a new area using engineered antibodies as therapeutic agents (Burioni et al., 1994; Burton et al., 1994; Crowe et al., 1994) . The present study illustrates the feasibility of obtaining human recombinant antibodies which recognize the target protein molecules by selection using peptides derived from the core and the E2 regions of HCV.
Methods
• Human sera. A patient of Italian origin (DG) suffering from liver cirrhosis was the source of the immune library. The patient's HCV was classified as type 1 by serotyping. A panel of 45 anti-HCV-positive and 23 anti-HCV-negative human serum samples was screened for reactivity by ELISA with various peptides spanning the HCV core, El, E2 and E2 hypervariable regions (HVR1) and used in the inhibition tests. All were blood donors from the East Anglian Blood Transfusion Centre or patients from Addenbrooke's Hospital, Cambridge.
• Peptides and protein. Thirty-four peptides, each 15-20 residues, were initiaIIy used as part of ongoing investigations into the serological detection of HCV in blood donations (Table 1) . They were derived mostly from the core, El, E2 and HVR1 regions of genotypes la and lb (Choo et al., 1991; Honda, GenBank no. X61596; Inchauspe et al., 1991; Okamoto eta] ., 1992a, b; Takamizawa et al., 1991) . Amino acid changes were introduced into a number of these sequences to test the effect of these substitutions on the immunogenicity of HCV.
Four non-overlapping core peptides were synthesized. The peptide spanning residues 66-80 was common to both genotypes la and lb (Inchauspe et al., 1991; Takamizawa et aI., 1991) whereas the peptide spanning residues 87-101 was derived from genotype Ia (Inchauspe et al., 1991) . Two peptides (residues 10-24 and 28-42) were synthesized with introduced amino acid changes based on the sequence of HCV-JKI (Honda, GenBank no. X61596). Eight E1 peptides spanning residues 216--333 were synthesized. Five were derived from the genotype lb (Honda, GenBank no. X61596), representing two groups of overlapping peptides. Based on the sequence of the same HCV strain, one peptide (residues 226-240) with introduced amino acid changes was synthesized. The other two were overlapping peptides from residues 294-318 derived from another lb genotype (Okamoto et al., 1992b) . Fifteen E2 peptides spanning two-thirds of the length of E2 beginning at the carboxyl end of the HVR1 (residues 406--670) were synthesized. Five were nonoverlapping peptides derived from genotype la . Two were derived from two different Ib genotypes (Honda, GenBank no. X61596; Takamizawa et al., 1991) . Changes were introduced into eight sequences based on that of Choo et al. (1991) , Okamoto et aI. (1992 b) and Honda (GenBank no. X61596), respectively. Seven E2 HVR1 peptides were derived from a sequence based on amino acid residues 14-28 of the HVR1. Variations were introduced into the sequence to generate seven novel sequences. Additional peptides with a cysteine residue added to the carboxyl terminus were synthesized in a later study to investigate the reactivity of scFvs with peptide variants (see Table 3 ). More peptides were synthesized according to the sequence of HCV-JK1 (Honda, GenBank no. X61596) later to cover most of the core, E1 and E2 regions to complete the study of serological detection of anti-HCVpositive human antibodies and the peptide sequences and the results will be published elsewhere.
These peptides were synthesized either by Cambridge Research Biochemicals or by Severn Biotech and used at 70-85 % purity. They were reconstituted in 4% (v/v) DMSO/H20 to a concentration of 1 mg/ml. Some of the peptides were synthesized with an additional cysteine residue at the C terminus. The peptides that contained a cysteinyl residue were coupled to BSA activated using the heterobifunctional cross-linker 3-maleimidobenzoic acid N-hydroxysuccinimide ester (MBS) (Sigma) (van Regenmortel et al., 1993) . Peptides that did not contain cysteine, including those used as selection agents for specific scFv, were pre-treated with 2-iminothiolane hydrochloride (Sigma) to add a small linker arm, having a sulphydryl function, to any amino groups that occurred either as part of any lysine side chain that might be present or at the amino terminus. Most of the subsequent investigations were made using peptides coupled to BSA as it was found that more consistent ELISA results were obtained from the use of the complex than the use of free peptides.
A purified recombinant HCV core protein expressed in Escherichia coli was obtained from J. Saldanha (National Institute of Biological Standards and Controls, Potters Bar, UK). An E2 protein expressed from mammalian Chinese hamster ovarian (CHO) cells and coated onto microparticles was kindly provided by J. Koziarz (Abbott Laboratories, USA). Because the E2 protein was expressed from mammalian cells, it is highly likely to be glycosylated.
• Construction of the library. A phage antibody library was constructed by cloning the IgG V H genes obtained from the HCV antibody-positive patient DG into a light chain library, pHEN-1-VL-re p (Schier et al., 1996) , carrying 4'5 x 106 copies of the V L genes from two HCV antibody-negative blood donors, pHEN-1-VL-re p was constructed by subcloning the V L genes amplified from a previously described IgG library (Marks eta] ., 1991a) into the XhoI and NotI sites of pHEN1-V;3 (Hoogenboom & Winter, 1992) . The V~I genes were obtained by nested PCR with family-based primers using cDNA template synthesized from an oligo(dT) primer as in Marks et al. (1991 b) . For a list of the primers 
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-I Genotyping according to the nomenclature in Simmonds et al. (1994) . :1: Letter in bold indicates amino acid residue change in relation to that of the reference sequence. § These peptides contain novel sequences derived from the HVR1.
HuIgG1-4CHIFOR, HuVHla-6aBACK and HuVHla-6aBACKSfi, see Marks et al. (1991a) . Additional primers were HUJHI-2FORSAL, 5' GAGTCATTCTCGTGTCGACACGGTGACCAGGGTGCC 3'; HUJH3FORSAL, 5' GAGTCATTCTCGTGTCGACACGGTGACCA-TTGTCCC 3'; HUJH4-SFORSAL, 5' GAGTCATTCTCGTGTCGAC-ACGGTGACCAGGGTTCC 3' and HUJH6FORSAL, 5' GAGTCATT-CTCGTGTCGACACGGTGACCGTGGTCCC 3'.
• Selection of scFv. Phagemid particles were rescued from the library, purified and concentrated (Griffiths et al., 1993) . Three rounds of selection were performed essentially as in Marks et al. (1991a) in immunotubes (Falcon 2052) coated by incubation with 5 p.g/ml of BSAcoupled peptides in PBS (0"9% NaC1 pH 7"2) overnight at room temperature.
• Restriction patterns of clones. The diversity of the original and the selected library was determined by the BstNI restriction patterns of inserts amplified by PCR with the primers LMB3 and fd-SEQ1 (Marks et aI., 1991a) .
• Induction of scFv expression. Single colonies of infected E. coli cells (strain HB~151 ) were induced to express soluble scFv as described (Marks et aI., 1991a) . In some experiments, the scFv production was scaled up and the scFv was concentrated 20-40-fold by precipitation with 40 % ammonium sulphate.
• Purification of scFv. scFv fragments were subcloned into the NcoI/NotI sites of the vector pUC119SfiNotHis6, a derivative of pHENI (Hoogenboom et aI., 1991) , which contains six histidine residues at the C terminus of the polylinker sites to enable affinity purification of the scFv with nickel-coated agarose beads. A 500 ml culture was induced to express the scFv (Marks et al., 1991a) , which was harvested from the periplasm by lysing the pelleted bacteria in 10 ml of ice-cold saline-EDTA (phosphate-buffered 1 M-NaC1, 1 mM-EDTA, pH 7-2) and incubating the lysate with 400 ~_l of Ni-NTA agarose resin (Qiagen) in saline--EDTA containing MgCI 2 (1-2 mM) for 1 h with rotation. After washing the resin three times with saline--EDTA, the bound scFvs were eluted twice with 100 ~l of saline--EDTA containing 250 mM-imidazole for 10 min. The scFv was dialysed against saline-EDTA and concentrated using Centricon 10 microconcentrators (Amicon). The purified scFv preparations were quantified by the Bio-Rad (Bradford) Protein Assay against a BSA standard and the reactivity tested by ELISA. The purity of the scFv was checked by SDS--PAGE (Laemmli, 1970) and Western blot iiiiiii ijilili!iiiiji!ji!iiii!i!iii!iiiiiiiiiiiii i !i iii ii (Towbin eta] ., 1979), using the monoclonal antibody (MAb) 9E10 [which recognizes the C-terminal peptide tag (Munro & Pelham, 1986) coexpressed with the scFv] and peroxidase-conjugated anti-mouse IgG (Sigma).
• ELISA. Detection of scFv reactivity was performed according to Ward et a] . (1989) except that the peptides were coated at 2-10 ~g/ml (concentrations refer to that of the BSA for BSA-coupled peptides) and the bacterial supernatant containing scFv in 1% skimmed milk powder/PBS (MPBS) was added to incubate for 90 min at room temperature. The core protein was used at 50 ~g/well. Bound scFv was detected with MAb 9E10 and peroxidase-conjugated anti-mouse IgG antibody.
To detect and titrate the anti-peptide antibodies in human sera, 100 p.1 of the peptides was coated at 2 l~g/ml in PBS pH 7'2 overnight at 4 °C. The subsequent steps were performed according to the anti-HCV ELISA (Abbott) using the kit reagents. Antibody detection results were expressed as 'sample-to-cut-off' ratios obtained from duplicate experiments. The cut-off value was calculated as 'mean + (3 x SD)' of at least 20 HCV-negative serum samples assayed separately.
• Inhibition ELISA. The optimal concentrations of the peptides used to coat the plate and of the scFv dilutions were determined by checkerboard titration (Rath et a] ., 1988). The dilution of scFv which resulted in approximately 40% reduction of the absorbance value after serial twofold dilution was mixed with various concentrations of BSAcoupled peptides, free peptides, or human sera in 1% MPBS before addition to the wells to incubate for 90 min at room temperature. The free blocking peptides were used at serial 10-fold dilutions beginning at I x 10 4 M. The BSA peptides were used with an initial value of 5 x 10 7 M (expressed as BSA concentration since the number of peptide molecules coupled to each molecule of BSA was not determined) and 5-fold serial dilutions. Human sera were used undiluted or serially diluted up to 1 : 64. The subsequent ELISA steps were similar to those described above for scFv ELISA. The degree of inhibition was measured as the percentage of the maximum absorbance obtained when scFv was incubated alone without competing peptides or sera.
• Sequencing, The sequences of the V H and V~ genes were obtained with an automated sequencer (ABI) using primers LMB3 (Marks et aI., 1991a) and LINK-SEQ (Hoogenboom & Winter, 1992) for the heavy chains and primers fd-SEQ1 (Marks et a] ., 1991a) and RC-LINKSEQ (CTCTGGCGGTGGCGGATCG) for the light chains. The sequences were compiled and analysed by the programs Sequence Navigator, MacVector 4.5 and AssemblyLIGN. The V H and V L genes were compared to germline gene segments present in the V BASE directory (Cook & Tomlinson, 1995) and to existing sequences available from the GenBank database (NCBI).
Results

Construction of an IgG immune phage display library
The VII and V L genes were cloned sequentially into a phagemid vector such that the 5' VII fragment would be joined to the 3" V L fragment by a linker. The V~ and V~ repertoires of two non-immune individuals were cloned into pHEN-V~3 to create a phagemid vector, pHEN-1-VL-rep, with a cloning site for the insertion of the V H fragments. The V H repertoire of an HCV-positive patient was amplified with IgG constant region primers, gel-purified and cloned into pHEN-1-VL-re p to generate a library of clones with complete V H and V L domains. DNA fingerprinting of colonies revealed diverse restriction patterns in the library of 9"1 x 106 clones containing both V H and V L fragments (data not shown).
Choice of synthetic peptides
In order to choose the most reactive peptides for selecting phage display antibodies, peptides reactive with the serum of patient DG (from which the antibody library was constructed) were tested by ELISA against a panel of 45 anti-HCV antibodypositive sera. The El, E2, core and E2 HVR1 BSA-coupled peptides 6, 10, 23 and 29, respectively, were the most reactive made from these regions (Table 2) , the numbers of sera reacting positively being 8, 5, 30 and 16, respectively. The average 'sample-to-cut-off' ratios in two experiments with these peptides and patient DG serum were I"5, 1"5, 1"8 and 2"6, respectively. These peptides were therefore chosen to select for phage-displayed antibodies.
Selections using E2-derived peptide 10
BstNI fingerprinting showed one dominant digestion pattern after the second and third round of selection of the phage library with the BSA-bound E2 peptide 10. The clones were ELISA-positive with the homologous peptide. The specificity of one of them, clone 9el, was confirmed by the finding that it only reacted with BSA-coupled or free homologous peptides but not with heterologous peptides from core (peptide 23), E1 (peptide 6), E2 HVR1 (peptide 29) or controls (i.e. BSA and DMSO) in ELISA; moreover, only soluble BSA-coupled or soluble free homologous peptides, but not heterologous peptides, BSA or DMSO, blocked the scFv binding and in a dose-dependent manner in the inhibition ELISA (data not shown).
Selections using core-derived peptide 23
Two populations of clones were selected on BSA-bound core peptide 23. One, with a dominant BstNl pattern, was selected after two rounds of selection and persisted as the dominant clone (clone 2f2) after another round of selection. A minor proportion of the clones (4/56) with another digestion pattern (clone 4c2), was also selected after two rounds of selection, but no longer persisted after the third round. These scFvs reacted specifically with BSA-coupled homologous peptide 23 but not with heterologous peptides from E1 (peptide 6), E2 (peptide I0), E2 HVR1 (peptide 29) or control (i.e. BSA) in ELISA; moreover, only soluble BSA-coupled homologous peptides blocked the scFv binding in inhibition ELISA (data not shown). However, clone 2f2 did not react with flee peptide 23 and was not further investigated.
Selections using El-and HVRl-derived peptides 6 and 29
With the EI peptide 6, after three rounds of selection, a few restriction patterns were displayed without a clearly dominant one but none of the expressed scFvs were reactive when tested against homologous peptide by ELISA. With the HVR1 :53~ peptide 29, no clones were selected after three rounds of selection.
Blocking of the binding of scFv 4c2 to homologous peptide by human sera
In the 45 member panel, 15 of the 30 anti-peptide 23-positive samples (Table 2) were available in sufficient quantity to be tested by inhibition ELISA for their ability to block the binding of scFv 4c2 to homologous peptide. Four were found to block the binding of scFv 4c2 to peptide 23 and there was a correlation between the titres of anti-peptide 23 serum antibodies and the ability to block [i.e. undiluted samples 005, 008, 236 and 006 with anti-peptide 23 titres of 1:12800, 1 : 1600, 1 : 1600 and 1 : 800 blocked the binding by 76 %, 69 %, 51% and 44%, respectively (Fig.I) ]. Sample 001 (1:1600) blocked marginally (Fig. 1) . All 10 serum samples with titres below 1:800 failed to block.
Concentrations of free peptides inhibiting scFv BSAcoupled peptide reactions
An estimate of the orders of magnitude of the affinity constant of the scFvs was made by inhibition ELISA using soluble free homologous peptides. The concentrations of peptides required for blocking 50 % binding of scFvs 9el and 4c2 to homologous BSA-bound peptides were of the orders of 1 x 10 -6 M--1 X 10 -7 M and 1 x 10 -5 M, respectively (Fig. 2) , suggesting that the values of the affinity constant may be of (Okamoto et al., 1992 c) 0"096/0'091 BSA NA NA 0"096/0"073 * These peptides are variants of that originally used in scFv selection. They were derived from other genotypes or were peptides with novel sequences. Apart from peptide 22, they were synthesized with an additional cysteine residue at the carboxyl terminal end, -I-Genotyping according to the nomenclature in Simmonds et al. (1994) . :1: scFv 9el was the specific clone selected on BSA-bound peptide I0; scFv 4c2 was a specific clone selected on BSA-bound peptide 23. § Expressed as a ratio of A450 of scFv to that of blank control by ELISA with BSA-coupled peptides as antigens. ]1 Similar results were obtained when free peptides were used as antigens. ,j Letter in bold indicates amino acid residue change in relation to that of the reference sequence.
the order of I x 106-1 x 10 v M for scFv 9el and I x l0 s M for scFv 4c2.
Reactions of scFv 9el with peptide variants
The reactivity of scFv 9el was tested against four peptide variants (22, $30, $31 and $32) derived from other HCV genotypes, which either contain amino acid changes from that of peptide 10 or are peptides overlapping the C terminus of peptide I0 (Table 3) .
ScFv 9ei selected on peptide 10 was also found to react with peptide 22 in ELISA, suggesting that the amino acid residues recognized by 9el were located within the sequence DFDQGWGPI common to both peptides I0 and 22 (Table 3) . Alteration of amino acid residues at either end did not affect reactivity. Both peptides 10 and 22 contain sequences related to genotypes la and lb but did not match any of the known sequences from existing genotypes. However, a search of GenBank database revealed the existence of the reactive sequence DFDQGWGPI in naturally occurring HCV variants [Choo et al., 199 I; Hall & Suzuki, GenBank no. L193 74, Kumar et al., 1992 (GenBank no. X84079); . The scFv 9el did not react with a closely related peptide, $30, which was derived from genotype lb (Honda, GenBank no. X61596) (Table 3 ). In this peptide the two aspartic acid residues of the reactive sequence DFDQGWGPI were substituted by arginine and alanine, suggesting that one or both of the aspartic acid residues are an obligatory part of the epitope. No reactivity was observed with overlapping peptides $3I (derived from genotype lb, Honda, GenBank no. X61596) and $32 (derived from genotype la; Choo et al., 1991) covering the carboxyl amino acid residues GWGPI, suggesting that residues towards the amino terminus are the sites of antibody recognition.
The same conclusion was reached by inhibition ELISA using soluble BSA-coupled or free variant peptides to block the binding of scFv 9el to immobilized BSA-coupled peptide 10. Only peptide 22 which contains the sequence DFDQGWGP] blocked, in a dose-dependent manner, to an extent similar to that of peptide 10 (data not shown).
Reaction of scFv 4c2 with peptide variants
The reactivity of scFv 4c2 was tested against three peptide variants ($6, $7 and $8) derived from other HCV genotypes, which contain amino acid changes from that of peptide 23 (Table 3) . ScFv 4c2 reacted with BSA-bound homologous peptide 23 which has a sequence common to both genotypes la and lb. When tested against peptide $7 (derived from genotype lb, Honda, GenBank no. X61596) and peptide $8 (derived from genotype 2a; Okamoto et al., 1992 c) in ELISA, no reactivity was observed. Moreover, scFv 4c2 did not react with BSA-bound peptide $6, which shares identical sequence with peptide 23 apart from the additional cysteine residue at the C terminus of peptide $6 (Table 3 ). This cysteine residue allowed coupling of $6 to BSA via the C-terminal residue whereas coupling of peptide 23 to BSA was through the Nterminal lysine residue. This suggests that coupling through either the carboxyl or the amino terminus greatly influences the peptide presentation. The amino acid residues reacting with scFv 4c2 probably reside at the carboxyl terminus so that when coupled to BSA through the carboxyl terminus as in the case of peptide $6, these residues are no longer available for antibody recognition.
The same conclusion was reached by inhibition ELISA using soluble BSA-coupled variant peptides. No significant blocking of the binding of scFv 4c2 to immobilized BSAcoupled peptide 23 was seen with soluble BSA-coupled peptide variants $6, $7, $8 or BSA (data not shown).
Reactions of scFvs 4c2 and 9el with core and envelope protein molecules
ScFv 4c2 reacted with an HCV core protein expressed from E. coli in ELISA with A492 of 0"872 (blank control = 0"148), suggesting that scFv 4c2 recognized an epitope on this protein.
Purified scFv 9el reacted with CHO-expressed E2 protein with average ratios of 3"1 and 5"4 over the blank controls at A45 o and A492 respectively.
V H and V L domain sequences
The sequences of the V H and V L of scFvs 9el and 4c2 can be obtained from the EMBL databases (accession numbers X97552-X97555). The scFv 9el and 4c2 VII gene segments were derived from the VH3 gent family and the V L gent segments from the V~I gent family. The scFv V H and V L variable gene segments showed differences from the closest matched germline genes, suggesting that they were somatically mutated. The significant differences observed between the V H genes of 4c2, 9el, the VT. gene of 4c2 and the germline genes b13/hv3019b13 (Olee et al., 199I) , WHG16 (Kuppers et al., 1992) , A20 (Lautner-Rieske et al., 1992) (19, 34, 21 nucleotide differences, respectively) suggests they may derive from as yet unknown germline genes.
Discussion
Phage display technology has proved useful for obtaining antibodies of human origin against poorly immunogenic antigens or those present in low plasma concentrations in the circulation (McCafferty et al., 1990) . This is particularly relevant for antibodies to the envelope proteins of HCV. Antibodies to the E2 glycoprotein were frequently found in infected patients but always in low concentrations (Chien et al., 1993) . We also found a poor reactivity of human sera with E2-derived peptides (Table 2) . Using phage technology we were able to obtain specific anti-E2 scFv from a phagemid library containing 9"1 x 106 diverse clones.
In most previous systems of scFv production, whole cells, native or purified antigens were used for the selection of phage displaying the scFv of interest (Marks et al., 1991a . In the present study, the feasibility of using synthetic peptides for selection has been demonstrated. We used a strongly serologically reactive core peptide and weakly reactive peptides from other regions of HCV (Table 2 ). Only the core and the E2 peptides were able to select binders from the recombinatorial library constructed from a patient who serologically reacted with all four peptides used for selection. The inability to select binders for the E1 and HVR peptides may be related to an insufficient representation of scFv diversity in the library or the low affinity of the specific scFvs rather than the absence of the corresponding antibodies in the individual's immune repertoire because in a later study we were able to select anti-HVR binders using four other peptides synthesized from the same region of HVR as in the present study (S. W. Chan, unpublished results) . Indeed the affinity of the selected scFvs in the present study is low (affinity constants -G< I x 10 v M) (Fig. 2) . The light chains of the present library derived from non-immune sources. A library constructed from the heavy and light chains of an immune source may enable us to obtain antibodies of higher affinity.
Although the peptides used in the selections were coupled to BSA, no BSA-specific binders were selected. The chance of selecting specific binders depends not only on the affinity of the scFvs but also on the efficiency and the number of rounds of selection. It was estimated that anti-BSA is present as one to two copies in the original naive IgM library of 2"9 x 107 clones (Marks et al., 199Ia) such that four rounds of enrichment (assuming a 50-fold enrichment each round) are required to select for anti-BSA binders. Sometimes such a protocol may not necessarily result in the selection of anti-BSA binders; using human synthetic libraries no anti-BSA were selected on haptens conjugated to BSA even after four rounds of selection (Hoogenboom & Winter, 1992) . We have performed three rounds of selection for each peptide and screening of at least 95 clones for each selection only revealed anti-peptide binders. Further rounds of selection may be required before we can detect anti-BSA binders. In contrast, the ease of isolating peptide binders after two rounds of selection may be due to the higher coating densities of the peptides on the solid phase.
The specificity of the scFvs was demonstrated by the specific blocking of scFv binding by homologous but not by heterologous peptides. Moreover, this blocking is dose dependent. For instance, binding of the anti-E2 scFv 9el to !53' immobilized peptide I0 was blocked by the soluble form of either free or albumin-coupled peptide I0. In contrast, the anticore scFv 4c2 was more sensitive to the presentation of the epitope. Only albumin-coupled peptides showed the expected specificity in both ELISA and inhibition ELISA whereas nonspecific blocking by heterologous competing free peptides was observed in a number of cases (S.-W. Chan, unpublished results). We suggest that cross-linking to the albumin carrier restricts the epitope presentation. The importance of the epitope presentation was further suggested by the inability of scFv 4c2 to recognize BSA-bound peptide $6, which shares the same sequence as peptide 23 apart from being linked to the carrier albumin through an additional cysteine residue at the carboxyl terminus instead of a lysine residue near the amino terminus as in peptide 23 (Table 3) . Furthermore, when free peptides 23 and $6 were used as coating antigens in ELISA, scFv 4c2 reacted with peptide 23 but not with $6. To account for this observation we suggest that when uncoupled peptides were bound to plastic the conformation was so constrained that in some cases no reactivity was found.
We showed that the binding of the anti-core 4c2 to homologous peptide was blocked by anti-HCV-positive human sera in an antibody-concentration-dependent manner, suggesting that the scFv recognized a similar, if not identical, epitope to those of one or more of the polyclonal antibodies present in the sera. We also obtained preliminary evidence of binding of the scFvs 4c2 and 9el to the recombinant core and E2 proteins, respectively. Since the synthetic peptides used are short and non-glycosylated, it seems likely that the viral epitope is linear and also non-glycosylated. This suggests that the anti-E2 scFv or other similar antibody fragments may be used as reagents in an HCV-capture assay. Those scFvs demonstrating cross-reactivity with HCV envelope neutralization epitopes common to various genotypes may have a potential use for anti-HCV immunotherapy.
